It could be a long while before we see a medtech venture capital financing year like 2021. Buoyed by mega rounds like CMR Surgical’s $600m Series D and Caris Life Science’s $830m growth equity raise, the medtech sector raked in almost $10bn over those twelve months, according to an analysis by Evaluate.
Since then, increased interest rates, poorly performing COVID-19 era investments and reopening of biotech M&A and IPO windows have drawn...